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Introduction: the changing therapeutic implications of nodal disease
Pelvic lymph node involvement is a powerful adverse prognostic factor in clinically localized prostate cancer. (Figure 1 ). 1 The incidence of nodal disease in men undergoing radical surgery for prostate cancer, which was as high as 30%, 2 has declined in recent years to near 5% with earlier diagnosis and more careful case selection. 3, 4 Identi®cation of node positive cases remains important both for prognostic purposes, and for determining appropriate management. Men known to have nodal disease have in the past been widely assumed to be incurable, and therefore were managed conservatively, using long-term androgen deprivation. So the motivation for identifying node positive men has been to spare them the rigours of radical treatment. However, data has accumulated which suggest both that a proportion of node positive men may be cured after all, 5 ± 11 and that in such cases there may be a signi®cant bene®t for combined modality therapy. 12 ± 14 RTOG 75-06 found a 10 y clinical cancer-free survival of 7% in men with pathologically proven nodal involvement who were treated with pelvic node dissection and radiotherapy, suggesting a curative role in a small proportion of cases for local therapy alone. 11 A retrospective comparison from MD Anderson, of 229 men with pathologically proven nodal disease, of whom 185 were managed by early androgen ablation and 44 by combined androgen ablation and radiotherapy, reported 5 y failure rates of 58% and 10%, respectively, suggesting a bene®t for the use of combined modality therapy over systemic treatment alone. 12 The results of a recently reported Swedish randomized study suggest that, in node positive patients, there may also be a bene®t for combined modality therapy over local treatment alone. 13 In this trial, patients were treated with radical radiotherapy after surgical lymph node staging. In addition, at the time of radiation, they were randomized between immediate bilateral orchidectomy on the one hand, and observation with delayed orchidectomy as required on the other. Despite the small number of men randomized (91) there was a signi®cant 10 y survival advantage for patients randomized to immediate orchidectomy. Although subgroup analyses must be interpreted with caution, particularly in such a small trial, the survival advantage was seen most clearly in the node positive group. The role of combined modality therapy for men with nodal disease is also supported by the results of a surgical series from the Mayo Clinic: 790 men with pT6 N disease treated with bilateral pelvic lymph node dissection (BPLND), radical prostatectomy and adjuvant androgen deprivation (most with bilateral orchidectomy at the time of surgery), were found to have an impressive 15 y cause-speci®c survival of 60%. 14 So the rationale for identifying nodal disease in clinically localized prostate cancer is changing. In future, a knowledge of nodal status may be important, not so much in determining whether or not to pursue a radical treatment approach, but rather in selecting between different radical options. Nodal status might determine the type of surgery, the radiation treatment volume, 15 or the need for adjuvant systemic therapy. 16 In this review, we shall discuss the three main ways of assessing nodal involvement, namely predictive nomograms, imaging studies and surgical methods. We shall then evaluate possible strategies for combining these approaches to lymph node staging in the light of the changing therapeutic implications of nodal disease.
Predictive nomograms
It is known that the probability of nodal involvement increases with increasing prostate speci®c antigen (PSA), biopsy grade and clinical T stage. Predictive nomograms de®ne the probability of nodal involvement for an individual patient based on the results from well-documented surgical series. The best known is that of Partin et al from Johns Hopkins, who pooled the results of over 4000 lymphadenectomies from three centres performed between 1982 and 1996. 17 A simpli®ed version of the results of their multivariate regression analyses is shown in Table 1 .
Similar studies performed by Bluestein et al 18 and by Narayan et al 19 based on smaller numbers, produced results consistent with Partin's. Roach has devised an equation (% Risk of involved nodes 2/3 PSA [(Gleason score 7 6) 6 10]), which provides a useful`rule of thumb' for calculating the probability of lymph node metastases in men with T1 and T2 tumours, which approximates the nomogram predictions. 20 The nomograms have the advantage that, unlike other staging modalities, they require no additional expense, and cause no morbidity. In addition, other factors which have prognostic signi®cance for nodal involvement on univariate analysis could be assessed by seeing the contribution, if any, they make when added to the model. For example, several groups have incorporated the extent and grade of tumour involvement in sextant biopsies into their logistic regression analysis. 21 ± 23 The predictive value of these factors was most convincingly demonstrated by Conrad et al who, based on their ®ndings in 344 patients, found that the number of biopsies containing Gleason grade 4 or 5 cancer, and the presence of any biopsy containing predominantly Gleason grade 4 or 5 disease, were the strongest predictors of nodal involvement, surpassing even PSA, overall Gleason score and T stage. 23 Using the resulting algorithm they were able to identify a low-risk group with three or fewer biopsies containing any Gleason grade 4 or 5 cancer, and no biopsies containing predominantly Gleason grade 4 or 5 disease, which comprised 80% of all their patients who underwent staging lymphadenectomy, and in whom only 2.2% were node positive. These potentially important results need to be validated on a separate data set. In addition, seminal vesicle biopsy results 24, 25 have been reported to predict for nodal disease, and should be incorporated in future multivariate analyses of predictors for lymph node involvement.
There are several limitations to the use of nomograms. First, the results may not apply to an independent patient population. Indeed a validation exercise by Kattan et al 26 showed that, while the Partin nomogram predictions were generally applicable to an independent data set, there were some notable discrepancies, particularly in men at high risk of nodal disease. For example, for men with a predicted risk of nodal involvement according to the nomogram of 50%, the actual risk of nodal disease was found to be only 20%. A second limitation is the dif®culty in applying the nomogram predictions to decisions concerning individual patient management. Nomograms may be useful in de®ning a group of men at very low risk of nodal involvement, who do not need staging BPLND before proceeding to radical treatment to the prostate (represented by the bold ®gures in Table 1 ). However, the remainder will have an 11 ± 50% risk of nodal disease. In these cases the nomogram results merely reinforce the desirability of further lymph node assessment. Review of 790 men with localized prostate cancer referred to the Royal Marsden Hospital for consideration of radical treatment between 1988 and 1998 showed 29% and 71% in the low and high risk groups for nodal involvement, respectively.
Imaging studies
CT is widely used for detecting lymphadenopathy in many clinical scenarios, but the relative absence of fat in the pelvis, the proximity of pelvic nodes to the vascular bundles, and the variability of normal pelvic vasculature can all make the detection of pelvic lymphadenopathy dif®cult. MRI can achieve better contrast between different soft tissues, but, in common with CT, using current techniques it will not detect nodal disease in the absence of nodal enlargement. Wolf et al have reviewed 18 CT and seven MRI studies on pelvic lymph node staging in clinically localized prostate cancer, taken from between 1980 and 1994. 27 The studies included a total of over 1300 patients who went on to BPLND, thus allowing correlation of the imaging and pathological ®ndings. Taking the weighted mean ®gures for all studies, there was no difference between the accuracy of CT and MRI in diagnosing lymph node involvement. Sensitivity was 36%, and speci®city 97%. However, the accuracy varied considerably between studies, suggesting that with optimum techniques and experienced personnel better results may be achieved. Of course the possibility of publication bias suggests that others, not included in this review, may have had even poorer results.
Another relevant publication is the meta-analysis of Scheidler et al, which included 37 studies involving over 2000 patients with imaging ± histologic correlation of pelvic lymph node status, but in the setting of cervical cancer. 28 They found no signi®cant differences in the accuracy of nodal staging between CT, MRI and lymphangiography. With a 20% pretest probability of pelvic lymph node disease, positive and negative MRI scans were associated with a post-test probability of 63% and 4%, respectively. If we could take these results at face value, and apply them to men with prostate cancer, it would imply that negative ®ndings on imaging were good evidence of the absence of nodal involvement. However, this con¯icts with the Wolf data, which, for a 20% prior probability of nodal disease, would suggest that a negative scan was associated with a post-test probability of as much as 14%. Both Wolf's review and Scheidler's meta-analysis imply that positive imaging results are inconclusive, and merely demonstrate the need for further investigation if a treatment decision rests on the issue.
Five ways in which the accuracy of staging using imaging might be improved are: (i) altering the size criteria for reporting nodal abnormality; (ii) combining imaging with guided ®ne needle aspiration cytology (FNAC); (iii) incorporating imaging results into predictive nomograms; (iv) using response to treatment as a sign of nodal involvement; and (v) using novel imaging techniques.
Size criteria for abnormal nodes
Most of the studies reviewed by Wolf used a cut-off value of 10 mm to identify involved nodes, but in others the ®gures was as high as 15 mm 29 or even 20 mm. 30 There is now evidence that even a cut-off of 10 mm may be too high.
Vinnicombe et al studied 40 men with stage 1 testicular germ cell tumours, who had initial staging CT scans including the pelvis, with bipedal lymphangiography performed 24 ± 48 h later, and then a follow-up CT scan 3 ± 4 months afterwards. 31 No patient had pelvic nodal metastases at any time, either before or after evaluation. The maximum short axis diameter (MSAD) of nodes was measured independently by two radiologists, and nodes were classi®ed into four anatomical areas ( Table 2) . Taking the 187 nodes seen on CT before lymphangiography, the median MSAD was 3 mm, with only three measuring 8 mm, and no nodes larger than 8 mm. Nodes were larger post-lymphangiogram than before, possibly because the nodes were engorged with oil, and possibly because the pre-lymphangiogram CT scans gave a spuriously small size related to volume averaging. However, of the 1801 nodes seen on CT after lymphangiography, 95% were still 9 mm or less. Node size also varied with anatomical site, with external iliac nodes being the largest, followed by common iliac, obturator, and with internal iliac nodes being smallest. The authors recommend that the upper limit of normal be taken as 7 mm for internal iliac, 8 mm for obturator, 9 mm for common iliac and 10 mm for external iliac, based on the results of the post-lymphangiography scans, and accepting a 5% false positive rate.
However, these results, obtained in healthy, young men, will not necessarily be applicable to older men with prostate cancer. Indeed, a series of 59 BPLNDs in men with clinically localized prostate cancer, obtaining an average of 20.5 nodes per patient, reported a mean nodè size' of 13.7 mm. Only 16 of the 59 cases had nodal involvement with cancer, so the authors concluded that reactive nodal enlargement was common in this group of men. 32 
Combining imaging with biopsy of suspicious nodes
Another way to improve the accuracy of imaging studies is to add some sort of pathological con®rmation of suspicious nodes, either by CT guided ®ne needle aspiration cytology (FNAC), or by open biopsy. The largest study of this approach comes from Van Poppel et al, in Leuven. 33, 34 They studied 285 patients with pathologically con®rmed, clinically localized prostate cancer, with a median initial serum PSA of 8.1 ng/ml, who were candidates for radical prostatectomy on the basis of clinical T stage and comorbidities. They staged the pelvis with a contrast enhanced CT scan with 10 mm cuts. In those men with CT evidence of pathological nodes, which they Lymph node staging CC Parker et al de®ned as the presence of any asymmetric node greater than 6 mm, one node was sampled by CT guided FNA, and two samples were taken for cytological examination. If cytology was equivocal, or the sample was insuf®cient, FNA was repeated. Those men with clearly malignant cytology were given hormone therapy only, and a reduction in size of the nodes on subsequent CT scan was interpreted as con®rmation of nodal involvement. All other men underwent bilateral pelvic lymphadenectomy and radical prostatectomy. The results are shown in Table 3 . This study shows unusually good sensitivity and speci®city for CTalone. This may well be a result of the 6 mm size criterion selected, and supports the conclusions of Vinnicombe et al 32 that the upper limit of normal for pelvic lymph node size should be lower than has previously been appreciated. Only 10 out of 285 (3.5%) men had involved lymph nodes not detected by imaging. This proportion is the same whether or not FNA is used, but assuming no change in imaging sensitivity, would vary depending on the characteristics of the population studied. This study had a true node-positive rate of only 16%. In a population with 30% of men node positive, which might be more representative of current UK practice, the proportion of false negatives might be expected to rise to 6.6%.
The bene®t of adding FNAC to CT was an improvement in speci®city. If the CTresults were taken at face value, eight out of 285 men with uninvolved lymph nodes would be inappropriately denied radical treatment, whereas with the addition of FNAC, none would be. Interestingly, seven out of the 35 cases with positive cytology were obtained from nodes measuring less than 10 mm in diameter which provides further justi®cation for reducing the previously accepted upper limit of normal size of pelvic lymph nodes. Unfortunately, with the exception of these seven cases, the diameter of the sampled nodes was not speci®ed. It may be possible to de®ne a lymph node size above which FNAC is unnecessary.
Limitations of the approach include the technical dif®-culties in obtaining samples safely from less accessible nodal groups, particularly in obese patients, and, of course, the failure to improve upon the sensitivity of CT alone. Although sensitivity might be increased by further reducing the size criteria for nodal abnormality, this would not only increase the need for FNAC, but also exacerbate the technical dif®culty of`hitting' the node.
Incorporating imaging results in predictive nomograms
Imaging results could be included as an extra variable, in addition to grade, PSA and clinical T stage, in multivariate regression analyses of lymph node involvement. This has yet to be done, but D'Amico et al have demonstrated the potential of this approach with regard to staging of the primary tumour. 35 
Hormone responsiveness as a sign of nodal disease
It may be that one could make use of the nodal response to androgen deprivation. A good response on a repeat scan after 3 months of hormone treatment might be considered evidence in favour of nodal involvement. Conversely, a node unchanged in size, in the presence of a good primary tumour response, might suggest that the node was not involved. While this policy might seem super®cially attractive, the behaviour of enlarged reactive lymph nodes cannot be predicted with any accuracy. Furthermore, this approach to staging cannot be rigorously validated, since pathological assessment of nodes after hormone treatment is not straightforward.
Novel imaging techniques
Advances in MRI Recent technical advances in MRI have led to the production of high quality fast imaging which permits the evaluation of contrast uptake by different tissues over a short period of time. Using this dynamic scanning technique, pre-and post-contrast images are obtained through a single slice (or several slices) at intervals of 1 ± 10 s for a period of several minutes. The precise details of the technique vary according to the manufacturer of the MR equipment, but in general, fast/turbo gradient echo T1-weighted images are obtained both before and after injection of a bolus of contrast material (gadolinium-DTPA).
In general, the enhancement characteristics of malignant lesions are signi®cantly different from benign lesions or normal tissue. 36 This is due to tumour neovascularity, the development of new blood vessels which are both more numerous than in normal tissue and abnormal, Table 3 Results of pelvic nodal staging in 285 men with clinically localized prostate cancer using CT scanning, either alone or in combination with ®ne needle aspiration cytology (FNAC) 33 Lymph node staging CC Parker et al having increased capillary permeability, altered vascular resistance and an increased number of arteriovenous shunts. 37 These abnormal vascular characteristics are re¯ected by early onset of enhancement and an early washout phase on dynamic scanning. These enhancement characteristics may be assessed visually, and are best shown on subtraction images of pre-and post-contrast scans. However, more accurate analysis can be achieved by placing a region of interest (ROI) on the area of enhancement within the image and then obtaining signal intensity ± time curves for the ROIs. Using this technique, dynamic contrast characteristics of different tissues and tumours can be assessed. Early results suggest that it may be a useful method of detecting metastatic lymph nodes (Figure 2) . In one study, metastases in normal sized nodes were detected using this technique. 36 However, enhancement of non-metastatic nodes may also occur and further investigation of this exciting advance is required to determine its sensitivity and speci®city in the diagnosis of nodal involvement.
Another new development in MRI is the introduction of a lymph node-speci®c contrast agent, Sinerem (Guerbet, Paris, France). This agent consists of ultra small (20 nm) superparamagnetic iron oxide particles (USPIO) which are taken up by macrophages within normal functioning nodes within 24 h of intravenous injection. The contrast agent reduces the signal intensity of normal lymphoid tissue within the node, whereas the tumour does not take up the contrast, and therefore no reduction in signal intensity is seen. Early results of this new agent are promising and it may be a particular advantage in increasing the speci®city of MR by reducing the number of false positive examinations. 38, 39 Lastly, techniques are being developed to permit percutaneous MR-guided biopsies. This technique is already being carried out in a few centres and has the advantage that normal sized nodes can be imaged in the most appropriate plane for access, whereas CT-guided biopsy is limited to the transaxial plane. However, currently the technique is slow and rather cumbersome to perform, and is therefore unlikely to replace CT-guided percutaneous techniques. 40 Radioimmunoscintigraphy (RIS) Attempts to image prostate cancer using labelled antibodies against PSA have been disappointing. 41 However, there is considerable interest in the potential of capromab pendetide, also known as CYT-356 (ProstaScint, Cytogen Corp), an indium ± labelled antibody that recognizes the intracellular domain of prostate speci®c membrane antigen (PSMA). ProstaScint scanning has been rapidly popularized in North America for the assessment of both localized and metastatic prostate cancer. Hinkle et al correlated the results of RIS using CYT-356 with lymphadenectomy ®ndings in 48 patients with clinically localized prostate cancer. 42 They demonstrated that tumour deposits as small as 5 mm could be detected in pelvic lymph nodes, and that the sensitivity and speci®city for the detection of nodal involvement, at 75% and 86% respectively, was superior to the results of CT and MRI. However, no detail is given on how these conventional imaging techniques were employed, and the results are no better than those achieved by others with standard imaging techniques. 33 In another study of pelvic nodal staging using ProstaScint scanning in 19 patients who went on to BPLND, Babaian et al reported 44% sensitivity and 86% speci®-city. 43 A larger, more recent, report has explored the utility of incorporating the results of ProstaScint scanning into predictive nomograms. 44 A total of 198 patients with clinical stage T2 or T3 prostate cancer, deemed to be at high risk of nodal disease on the basis of presenting PSA, grade or T stage, but without evidence of nodal enlargement on CT/MRI, underwent ProstaScint scanning prior to BPLND. Once again, no details were given concerning the conventional imaging techniques used and, in particular, the size cut-off for nodal enlargement was not stated. Some 72 cases had abnormal ProstaScint scans, of whom 48 were among the 78 patients subsequently found to be pathologically node positive, giving a sensitivity of 61.5%, and a speci®city of 80%. Combining the scan results with, for example, Partin's nomogram increased the area under the receiver operating characteristic (ROC) curve for predicting nodal involvement from 0.6 to 0.75, demonstrating that the addition of ProstaScint scan results improved the performance of the nomogram. However, this series comprised a markedly adverse case mix, with a median PSA of 35 ng/ml, and with 39% node positive. The apparent bene®t seen for the addition of ProstaScint scanning may not apply to the more favourable case mix typically seen in clinical practice. Furthermore, ProstaScint scanning is technically demanding, and the US Food and Drug Administration Advisory Panel has recommended that scans should only be performed by physicians speci®cally trained in reading these images. Antibodies are being developed which recognize the extracellular domain of PSMA, and these may provide greater sensitivity.
Positron emission tomography (PET) PET using 2-deoxy-2-uoro-D-glucose (FDG) has been used to image metastatic prostate cancer, but with no better results than standard imaging techniques. 45, 46 FDG uptake was found to be relatively low compared with that in other tumour types, so there is a need for a more suitable radiotracer before PET is evaluated in the setting of initial staging of prostate cancer.
Staging lymphadenectomy
Bilateral pelvic lymphadenectomy is the gold standard to determine the nodal status of clinically localized prostate cancer. Open staging lymphadenectomy has been used frequently in the US since the 1970s, and has generally been performed with frozen section analysis of the dissection specimen, to allow, in node negative cases, radical retropubic prostatectomy at the same sitting. Most surgeons limit the node dissection to between the bifurcation of the common iliac vessels superiorly, the pelvic¯oor inferiorly, the medial border of the external iliac vessels laterally and the hypogastric vessels medially. This includes hypogastric and obturator nodes, and most external iliac nodes, but leaves common iliac, pre-sacral and lateral sacral nodal groups, as well as nodes lying between the external iliac vessels. Complications of open pelvic lymphadenectomy include lymphocoele formation, infection, obturator nerve injury, thromboembolism, lymphoedema, and iliac vessel haemorrhage, and are typically seen in 7 ± 15% of cases. 47, 48 One would also expect increased radiation morbidity in those men subsequently receiving pelvic radiotherapy. Open BPLND, as described, is becoming less common, partly because it is now appreciated that frozen section examination of pelvic nodes carries a signi®cant false negative rate 49 and partly because of the availability of less morbid alternatives. Laparoscopic lymphadenectomy and lymphadenectomy at`minilaparotomy' have been developed in the hope of reducing the morbidity of surgical staging. Laparoscopic lymphadenectomy can obtain a similar nodal yield to that of the open procedure, with a much shorter post-operative recovery. 50 However, it requires expensive equipment, can take 3 h or more to perform, and is not without morbidity, including a risk of bowel injury, particularly in inexperienced hands. 51 The risk of bowel complications can be minimized by adopting an extraperitoneal technique. 52 Of all the surgical methods, minilaparotomy BPLND may provide the best combination of ef®cacy, convenience, cost and morbidity. Brant et al, in a study of 51 men who had minilaparotomy BPLND, 53 found that the procedure could be performed in approximately 35 min, with the same nodal yield as for laparoscopy but at half the cost. They reported no morbidity and that the procedure was performed as a day-case in all but one case. Another report compared 22 men who underwent minilaparotomy BPLND with 22 who had laparoscopic BPLND. In this study minilaparotomy was associated not just with a shorter operating time (1.2 vs 2.9 h) and hospital stay (1.5 vs 2.6 days), but also less morbidity (9% vs 32%) and, once again, a ®nancial saving compared with laparoscopic BPLND. 54 Lymphadenectomy is the most accurate method of lymph node staging in prostate cancer and, unlike imaging and nomograms, when positive provides proof of nodal disease. However, although it is regarded as the gold standard against which other staging modalities are judged, it is still fallible. Typical yields are of the order of 10 ± 20 nodes per patient. This is considerably fewer than the 43.5 nodes visualized per patient in Vinnicombe's study, 31 and fewer than that which can be obtained by an extended BPLND which includes pre-sacral, lateral sacral and common iliac nodes. A series of 30 men who underwent extended BPLND for prostate cancer yielded a mean of 43 nodes per patient. 55 In this series 15 cases were node positive, of whom eight had pre-sacral, and seven lateral sacral disease. Importantly, in two cases, nodal disease was con®ned to the pre-sacral or lateral sacral groups. In another report, of nine patients found to be node positive at extended BPLND, two were found to have nodal disease outside the usual target for a modi®ed BPLND. 56 These two reports of extended BPLND are based on small numbers, but they cast doubt on the sensitivity of BPLND as it is commonly practised for nodal staging and so are potentially very important. Until similar, larger studies are performed, the typical BPLND is probably better regarded as a sampling procedure than as a radical cancer operation. It would be interesting to know the frequency with which men recur in the pre-sacral and pre-sciatic nodes after BPLND and radical prostatectomy, but such information is hard to obtain because many men receive androgen deprivation for PSA failure before the sites of recurrent disease become apparent.
A comparison of alternative approaches to lymph node staging Table 4 shows a comparison of alternative approaches to lymph node staging in 100 men with clinically localized prostate cancer, of whom 20 are assumed to be truly node positive. Approach 1 is the typical North American surgical practice in which BPLND is performed in men deemed at higher risk of nodal disease according to predictive nomograms. 57 In this model we have assumed that the sensitivity of the nomogram is 90%, with a 53% speci®city, 17 and that BPLND has a sensitivity and speci®city of 100%. Most UK centres do not use surgical staging, but rely on imaging with either CT or MRI (approaches 2 and 3). Approach 2 assumes an imaging sensitivity of 36% with a speci®city of 97%, in accordance with the results of Wolf's review, 27 whereas approach 3 assumes a sensitivity of 78% and a speci®city of 97%, which were the ®ndings of Van Poppel's group. 33 The addition of FNAC in those cases that are node positive on imaging is shown in approach 4, using a sensitivity of 78% and a speci®city of 100%, as found in Van Poppel's study. 33 Approach 5 represents an alternative in which imaging is restricted to patients at high risk of nodal disease according to the nomogram.
The table should be interpreted with some caution as the ®gures are dependent on the validity of the underlying assumptions. For example, if the proportion of node positive men was not 20%, but 30%, then the false negative rate for imaging (approach 2) could be as high as 20%. Even accepting the table at face value, it is still dif®cult to compare the different approaches because judgements must be made between, for example, the morbidity, time and expense of BPLND on the one hand, against the relative inaccuracy of alternative methods on the other. There is a trade-off between the inappropriate Another complicating factor is the use of imaging studies for other purposes. In centres which use MRI scanning for staging the primary tumour, there is a case for imaging the pelvic nodes at the same time. Men being worked up for radical radiotherapy will also routinely undergo CT scanning of the pelvis for treatment planning purposes, and most centres insist on a diagnostic CT scan before the treatment planning scan is performed. For these reasons, the use of the nomogram to select patients for imaging (approach 5) may not reduce the need for scanning as much as is indicated in the table.
The comparison between different approaches to staging must also be performed in the light of one's treatment philosophy, and the decision which rests on nodal status. If, as has been widely accepted in the UK, men deemed`node-positive' are regarded as incurable, and are managed by androgen deprivation alone, then it is important to avoid false positives, so as not to deny any node negative men potentially curative treatment, whereas false negatives are less important. According to this philosophy, any staging method with good speci®city, even if it is no more sensitive than the Wolf imaging data, is not unreasonable. (The addition of guided FNAC to imaging is particularly attractive, with between 4.5 and 9 cases undergoing FNAC, according to imaging sensitivity, to prevent one man being wrongly denied radical treatment.) If, however,`node-positive' men are considered curable, and receive radical treatment to the prostate and pelvis, while`node negative' men receive radical treatment to the prostate alone, then it is the false negatives which are more important, and more sensitive methods of staging, such as with surgery (approach 1) are required. The contrasting practices between different countries with regard to pelvic node staging probably re¯ect this difference in treatment philosophy as much as other factors such as the availability of resources.
Conclusions
In the light of the recent data from the RTOG, 11 the Mayo Clinic 14 and the Swedish trial, 13 there is a strong case for adopting a radical, combined modality approach to treating some men with node positive prostate cancer. This has major implications for the way that we stage the disease, since a false negative rate of 13%, by effectively denying one in eight men a chance of a cure, is no longer acceptable. We should reconsider the merits of staging pelvic lymph node dissection, which offers greater sensitivity for detecting nodal disease, and may also have, previously unsuspected, therapeutic bene®t. However, the widespread introduction of surgical staging in the UK would, of course, have huge resource implications, and`state of the art' imaging may be almost as accurate. This highlights the need for further studies correlating imaging results with pathological ®ndings. Ideally, these studies should use the advances in imaging techniques discussed earlier, and extended rather than limited lymph node dissection. Pending the results of these studies, centres staging pelvic lymph nodes using imaging should adopt the size criteria of normality recommended by Vinnicombe et al. 31 Guided FNAC or minilaparotomy BPLND may be used to establish the status of equivocal lymph nodes if this information will alter patient management.
